Watch GOVX. Know when insiders buy.
One email the day a filing lands. Free.
GOVX
GeoVax Labs, Inc.
0.41
−0.01 −3.34%
USD · close Sep 16
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $3MP/E —DIV YIELD —FCF YIELD -615.49%REV TTM —NET INCOME −$20.4MNET CASH —52W 0.41 – 17.00SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$4.4M | −$4.4M | — | -0.97 | −$3.7M | $0 | −$3.7M | Jul 27 |
| Q1 2026 · Mar 31 | — | — | — | −$5.3M | −$5.3M | — | -2.62 | −$3.5M | $0 | −$3.5M | Jul 27 |
| Q4 2025 · Dec 31derived | — | — | — | −$4.4M | −$4.4M | — | -21.43 | −$5M | $0 | −$5M | May 14 |
| Q3 2025 · Sep 30 | — | — | — | −$6.4M | −$6.3M | — | -0.31 | −$6.2M | $0 | −$6.2M | Nov 13 |
| Q2 2025 · Jun 30 | — | — | — | −$5.4M | −$5.4M | — | -8.74 | −$4.3M | $11K | −$4.3M | Jul 27 |
| Q1 2025 · Mar 31 | — | — | — | −$5.4M | −$5.4M | — | -11.20 | −$6M | $17K | −$6M | Jul 27 |
| Q4 2024 · Dec 31derived | — | — | — | −$8.3M | −$8.3M | — | -115.94 | −$7.8M | $0 | −$7.8M | Apr 15 |
| Q3 2024 · Sep 30 | — | — | — | −$5.9M | −$5.8M | — | -0.91 | −$9.3M | $21K | −$9.3M | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$5.1M | −$5.1M | — | -1.99 | −$1.9M | $0 | −$1.9M | Nov 13 |
| Q1 2024 · Mar 31 | — | — | — | −$5.9M | −$5.9M | — | -2.47 | −$5.7M | $0 | −$5.7M | Nov 13 |
| Q4 2023 · Dec 31derived | — | — | — | −$7.7M | −$7.6M | — | -3.87 | −$10.3M | $19K | −$10.3M | Mar 27 |
| Q3 2023 · Sep 30 | — | — | — | −$8.6M | −$8.4M | — | -4.75 | −$5.1M | $6K | −$5.1M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$21.6M | −$21.5M | — | -22.40 | −$21.5M | $28K | −$21.5M | — | — |
| FY2024 · to Dec 31 | — | — | −$25.1M | −$25M | — | -120.46 | −$24.7M | $21K | −$24.7M | — | — |
| FY2023 · to Dec 31 | — | — | −$26.7M | −$26M | — | -14.29 | −$25.2M | $49K | −$25.2M | — | — |
| FY2022 · to Dec 31 | — | — | −$14M | −$14M | — | -12.39 | −$19M | $134K | −$19.2M | — | — |
| FY2021 · to Dec 31 | — | — | −$18.7M | −$18.6M | — | -3.04 | −$11.2M | $48K | −$11.2M | — | — |
| FY2020 · to Dec 31 | — | — | −$2.8M | −$3M | — | -2.14 | −$2.8M | $157K | −$2.9M | — | — |
Every number comes from GeoVax Labs, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.